Eli Lilly and Company LLY
1,183.46
1.57
0.13%
as of 25 Sep
- Market cap
- $1.11T
- P/E
- 39.7×
Follow LLY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Eli Lilly and Company (LLY) P/S ratio
As of 25 September 2026, Eli Lilly and Company (LLY) trades at a P/S ratio of 13.3×. Over the past ten years it has ranged from 3.3× (December 2016) to 22.8× (June 2024); the current reading is higher than 77% of that period. That is above the Drug Manufacturers General industry median of 3.3× and above the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 14.8× | (4.15%) |
| FY2024 | 15.4× | (1.20%) |
| FY2023 | 15.6× | 35.48% |
| FY2022 | 11.5× | 30.35% |
| FY2021 | 8.8× | 41.66% |
| FY2020 | 6.2× | 13.90% |
| FY2019 | 5.5× | (0.92%) |
| FY2018 | 5.5× | 24.06% |
| FY2017 | 4.5× | 19.89% |
| FY2016 | 3.7× | (17.02%) |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 13.4× | 17.99% |
| Mar 2026 | 11.4× | (23.03%) |
| Dec 2025 | 14.8× | 28.46% |
| Sep 2025 | 11.5× | (12.37%) |
| 42 more quarters | Free account |
Against its own ten years
Low 3.3×
High 22.8×
Ten-year median
6.3×
Current reading's percentile
77
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| PFE Pfizer Inc. compare | 2.6× |
| AZN AstraZeneca PLC compare | 4.2× |
| NVS Novartis AG compare | 4.9× |
| MRK Merck & Co., Inc. compare | 5.5× |
| AMGN Amgen Inc. compare | 5.9× |
| GILD Gilead Sciences, Inc. compare | 6.2× |
| JNJ Johnson & Johnson compare | 6.7× |
| ABBV AbbVie Inc. compare | 7.3× |
| LLY Eli Lilly and Company | 13.3× |
| Drug Manufacturers General industry median | 3.3× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on LLY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement